Document Detail


Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
MedLine Citation:
PMID:  22499288     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND:: The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study has previously demonstrated a beneficial effect of losartan compared to atenolol-based antihypertensive treatment in patients with essential hypertension and left-ventricular hypertrophy (LVH). However, patient age often influences the choice of antihypertensive drugs. Therefore, we investigated the influence of age on the effects of losartan versus atenolol-based antihypertensive treatment. METHODS:: A total of 9193 hypertensive patients with LVH aged 45-83 years were followed for a mean of 4.8 years. Blood pressure, high-density lipoprotein cholesterol (HDL-C), Sokolow-Lyon voltage, Cornell voltage-duration product and urine albumin-creatinine ratio (UACR) were measured yearly throughout the study. Patients were divided into two age groups according to the median age of 67 years and the effects of losartan versus atenolol-based antihypertensive treatment on the primary composite endpoint (CEP) consisting of cardiovascular death, nonfatal stroke or nonfatal myocardial infarction were investigated. RESULTS:: The beneficial effect of losartan versus atenolol-based treatment was greater in the group of patients older than 67 years [hazard ratio 0.79 (0.69-0.91), P = 0.001] compared to the group of patients younger than 67 years [hazard ratio 1.03 (0.82-1.28), P = 0809], P = 0.045 for interaction. The beneficial effects of losartan versus atenolol-based antihypertensive treatment on pulse pressure, HDL-C, UACR, and Cornell and Sokolow-Lyon voltage were not more pronounced in patients older than 67 years compared to patients younger than 67 years. All five risk factors considered as time-varying covariates predicted CEP independently (P < 0.01) with the exception of pulse pressure (P = 0.37) and the interaction between age and treatment on outcome remained significant (P = 0.042). CONCLUSIONS:: We showed a greater beneficial effect of losartan versus atenolol-based antihypertensive treatment in the group of patients older than 67 years compared to the group of patients younger than 67 years. This difference was not explained by a more pronounced effect of losartan-based treatment on any of the cardiovascular risk factors demonstrated to have independent prognostic importance.
Authors:
Anne C H Ruwald; Bo Westergaard; Thomas Sehestedt; Sverre E Kjeldsen; Lars H Lindholm; Kristian Wachtell; Richard B Devereux; Hans Ibsen; Markku S Nieminen; Björn Dahlöf; Michael H Olsen
Related Documents :
22591408 - Health-related quality of life and cost-effectiveness of treatment in subarachnoid haem...
22187318 - Outcome of kidney allograft in patients with adulthood-onset focal segmental glomerulos...
22755998 - Su-e-j-29: evaluation of effectiveness of immobilization devices for radiation therapy ...
21616558 - Narrowband ultraviolet b phototherapy for the treatment of steroid-refractory and stero...
17670038 - Irrigated radiofrequency ablation is a safe and effective technique to treat chronic at...
3065338 - Use of 5% sulfamylon (mafenide) solution after excision and grafting of burns.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-11
Journal Detail:
Title:  Journal of hypertension     Volume:  -     ISSN:  1473-5598     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
aDepartment of Internal Medicine, Glostrup Hospital, Glostrup, Denmark bDepartment of Cardiology, Oslo University Hospital, Ullevaal, Oslo, Norway cDepartment of Public Health and Clinical Medicine, Umea University, Umea, Sweden dDepartment of Cardiology, Gentofte University Hospital, Hellerup, Denmark eNew York Hospital - Cornell Medical Center, New York, USA fDivision of Cardiology, Holbæk Hospital, Holbæk, Denmark gHelsinki University Central Hospital, Helsinki, Finland hDepartment of Medicine, Sahlgrenska Sjukhuset Östra, Göteborg, Sweden iDepartment of Endocrinology, Odense University Hospital, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Random Composites of Nickel Networks Supported by Porous Alumina Toward Double Negative Materials.
Next Document:  Home versus ambulatory and office blood pressure in predicting target organ damage in hypertension: ...